STOCK TITAN

Vor Biopharma (VOR) 10-K Filings

VOR NASDAQ

Here are the 10-K annual reports from Vor Biopharma Inc. (VOR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.

Rhea-AI Summary

Vor Biopharma Inc. is repositioning itself as an autoimmune-focused biopharmaceutical company centered on telitacicept, a BAFF/APRIL‑targeting fusion protein in-licensed from RemeGen in June 2025. Telitacicept is already approved in China for SLE, RA and gMG, with additional Biologics License Applications pending for Sjögren’s disease and IgA nephropathy.

The company now leads global Phase 3 trials in generalized myasthenia gravis and Sjögren’s disease to support potential approvals in the United States, Europe and Japan, leveraging extensive Chinese Phase 3 data showing durable efficacy and a favorable safety profile. Earlier oncology and cell therapy programs, including trem-cel and VCAR33, have been discontinued and related intellectual property sold.

Under the telitacicept license, Vor paid a $125 million upfront (including a warrant for 16,000,000 shares) and owes up to $330 million in regulatory and $3.775 billion in sales milestones, plus tiered royalties. In March 2026 it agreed to a $75.0 million private placement of 5,338,078 shares at $14.05 per share with TCGX affiliates, and has granted registration rights for resale. A 1‑for‑20 reverse stock split was effected in September 2025, and 48,847,504 common shares were outstanding as of March 23, 2026.